Category Archives: Stem Cell Treatment


Exosomes: Definition, Function and Use in Therapy – Technology Networks

What are exosomes?

Exosomes are a class of cell-derived extracellular vesicles of endosomal origin, and are typically 30-150 nm in diameter the smallest type of extracellular vesicle.1 Enveloped by a lipid bilayer, exosomes are released into the extracellular environment containing a complex cargo of contents derived from the original cell, including proteins, lipids, mRNA, miRNA and DNA.2 Exosomes are defined by how they are formed through the fusion and exocytosis of multivesicular bodies into the extracellular space.

Multivesicular bodies* are unique organelles in the endocytic pathway that function as intermediates between early and late endosomes.3 The main function of multivesicular bodies is to separate components that will be recycled elsewhere from those that will be degraded by lysosomes.4 The vesicles that accumulate within multivesicular bodies are categorized as intraluminal vesicles while inside the cytoplasm and exosomes when released from the cell.

*Confusingly, there is inconsistency in the literature; while some sources differentiate multivesicular bodies from late endosomes, others use the two interchangeably.

Exosomes are of general interest for their role in cell biology, and for their potential therapeutic and diagnostic applications. It was originally thought that exosomes were simply cellular waste products, however their function is now known to extend beyond waste removal. Exosomes represent a novel mode of cell communication and contribute to a spectrum of biological processes in health and disease.2One of the main mechanisms by which exosomes are thought to exert their effects is via the transfer of exosome-associated RNA to recipient cells, where they influence protein machinery. There is growing evidence to support this, such as the identification of intact and functional exosomal RNA in recipient cells and certain RNA-binding proteins have been identified as likely players in the transfer of RNA to target cells.5,6 MicroRNAs and long noncoding RNAs are shuttled by exosomes and alter gene expression while proteins (e.g. heat shock proteins, cytoskeletal proteins, adhesion molecules, membrane transporter and fusion proteins) can directly affect target cells.7,8Exosomes have been described as messengers of both health and disease. While they are essential for normal physiological conditions, they also act to potentiate cellular stress and damage under disease states.2

Multivesicular bodies are a specialized subset of endosomes that contain membrane-bound intraluminal vesicles. Intraluminal vesicles are essentially the precursors of exosomes, and form by budding into the lumen of the multivesicular body. Most intraluminal vesicles fuse with lysosomes for subsequent degradation, while others are released into the extracellular space.9,10 The intraluminal vesicles that are secreted into the extracellular space become exosomes. This release occurs when the multivesicular body fuses with the plasma membrane.

The formation and degradation of exosomes.

This is an active area of research and it is not yet known how exosome release is regulated. However, recent advances in imaging protocols may allow exosome release events to be visualized at high spatiotemporal resolution.11

Exosomes have been implicated in a diverse range of conditions including neurodegenerative diseases, cancer, liver disease and heart failure. Like other microvesicles, the function of exosomes likely depends on the cargo they carry, which is dependent on the cell type in which they were produced.12 Researchers have studied exosomes in disease through a range of approaches, including:

In cancer, exosomes have multiple roles in metastatic spread, drug resistance and angiogenesis. Specifically, exosomes can alter the extracellular matrix to create space for migrating tumor cells.13,14 Several studies also indicate that exosomes can increase the migration, invasion and secretion of cancer cells by influencing genes involved with tumor suppression and extracellular matrix degradation.15,16Through general cell crosstalk, exosomal miRNA and lncRNA affect the progression of lung diseases including chronic obstructive pulmonary disease (COPD), asthma, tuberculosis and interstitial lung diseases. Stressors such as oxidant exposure can influence the secretion and cargo of exosomes, which in turn affect inflammatory reactions.17 Altered exosomal profiles in diseased states also imply a role for exosomes in many other conditions such as in neurodegenerative diseases and mental disorders.18,19Cells exposed to bacteria release exosomes which act like decoys to toxins, suggesting a protective effect during infection.20 In neuronal circuit development, and in many other systems, exosomal signaling is likely to be a sum of overlapping and sometimes opposing signaling networks.21

Exosomes can function as potential biomarkers, as their contents are molecular signatures of their originating cells. Due to the lipid bilayer, exosomal contents are relatively stable and protected against external proteases and other enzymes, making them attractive diagnostic tools. There are increasing reports that profiles of exosomal miRNA and lncRNA differ in patients with certain pathologies, compared with those of healthy people.17 Consequently, exosome-based diagnostic tests are being pursued for the early detection of cancer, diabetes and other diseases.22,23Many exosomal proteins, nucleic acids and lipids are being explored as potential clinically relevant biomarkers.24 Phosphorylation proteins are promising biomarkers that can be separated from exosomal samples even after five years in the freezer25, while exosomal microRNA also appears to be highly stable.26 Exosomes are also highly accessible as they are present in a wide array of biofluids (including blood, urine, saliva, tears, ascites, semen, colostrum, breast milk, amniotic fluid and cerebrospinal fluid), creating many opportunities for liquid biopsies.

Exosomes are being pursued for use in an array of potential therapeutic applications. While externally modified vesicles suffer from toxicity and rapid clearance, membranes of naturally occurring vesicles are better tolerated, offering low immunogenicity and a high resilience in extracellular fluid.27 These naturally-equipped nanovesicles could be therapeutically targeted or engineered as drug delivery systems.

Exosomes bear surface molecules that allow them to be targeted to recipient cells, where they deliver their payload. This could be used to target them to diseased tissues or organs.27 Exosomes may cross the blood-brain barrier, at least under certain conditions28 and could be used to deliver an array of therapies including small molecules, RNA therapies, proteins, viral gene therapy and CRISPR gene-editing.

Different approaches to creating drug-loaded exosomes include27:

Exosomes hold huge potential as a way to complement chimeric antigen receptor T (CAR-T) cells in attacking cancer cells. CAR exosomes, which are released from CAR-T cells, carry CAR on their surface and express a high level of cytotoxic molecules and inhibit tumor growth.29 Cancer cell-derived exosomes carrying associated antigens have also been shown to recruit an antitumor immune response.30

The purification of exosomes is a key challenge in the development of translational tools. Exosomes must be differentiated from other distinct populations of extracellular vesicles, such as microvesicles (which shed from the plasma membrane, also referred to as ectosomes or shedding vesicles) and apoptotic bodies.31 Although ultracentrifugation is regarded as the gold standard for exosome isolation, it has many disadvantages and alternative methods for exosome isolation are currently being sought. Exosome isolation is an active area of research (see Table 1) and many research groups are seeking ways to overcome the disadvantages listed below, while navigating the relevant regulatory hurdles along the way.

Produces a low yield and low purity of the isolated exosomes as other types of extracellular vesicles have similar sedimentation properties.

Low efficiency as it is labor-intensive, time-consuming and requires a large amount of sample. specialized equipment. High centrifugal force can damage exosome integrity

See the article here:
Exosomes: Definition, Function and Use in Therapy - Technology Networks

First COVID-19 Convalescent Plasma DonorCanadian Blood Services begins collecting plasma donations from people who have recovered from COVID-19 as…

VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) -- Canadian Blood Services is proud to be part of CONCOR, a national clinical trial to test the safety and effectiveness of COVID-19 convalescent plasma as a possible treatment to help patients infected with the virus. Today, the national blood authority and operator collected its first COVID-19 convalescent plasma donation in Vancouver.

Im delighted to be able to help out a really good cause. I have been an active blood donor for 15 years. Im pleased my unfortunate situation can help somebody else. I think Im doing a little bit of good out of all this. says Jerry Glubisz, Canadian Blood Services first COVID-19 convalescent plasma donor.

Canadian Blood Services is establishing a national convalescent plasma collection program. The blood operator is now recruiting potential convalescent plasma donors across the country through its new online registry.

Convalescent plasma may help patients recover from COVID-19, but this has not yet been proven. Well-designed clinical trials, like CONCOR, will help provide the necessary information about whether this is a safe and effective treatment option for patients, says Dr. Dana Devine, chief scientist with Canadian Blood Services. Were making an important contribution to research on a global scale that could help patients in Canada and around the world.

Over the next few weeks more convalescent plasma donors, like Jerry Glubisz, may donate at one of 11 Canadian Blood Services donor centres that have the capability to collect blood components, like plasma, through a process called apheresis. These donor centres are located in Vancouver, Calgary, Edmonton, Saskatoon, Regina, Winnipeg, London, Hamilton, Toronto, Ottawa and Halifax.

Initially, all convalescent plasma donations will be supplied to Canadian physicians caring for patients with COVID-19 in the context of the CONCOR trial and under the authorization of Health Canada.

Including both of Canadas public blood operators (Canadian Blood Services and Hma-Qubec), there are 10 research teams and more than 50 hospitals across the country currently participating in CONCOR. Patient involvement in the clinical trial will be determined by their treating physician at a participating hospital in consultation with the patient and/or the patients family. Patients with COVID-19 who are looking for more information on convalescent plasma as a treatment option are encouraged to visit CONCOR1.ca.

While Canadian Blood Services has officially started collecting convalescent plasma, these donations must still undergo all necessary testing and processing before being issued for use by physicians, as per blood safety and quality standards. Transfusions of convalescent plasma are expected to begin within a few weeks when the trial begins.

A convalescent plasma donation is the same as a plasma donation; however, a specific donor is needed for this clinical trial. In addition to meeting Canadas current plasma donor eligibility criteria, convalescent plasma donors must be younger than 67 years of age, previously confirmed positive for COVID-19 by a laboratory test, and fully recovered from the virus and symptom free for at least 28 days to participate. Donors must also live within driving distance of a donor centre located in one of the aforementioned cities. Anyone who meets these requirements is encouraged to join Canadian Blood Services online registry. Additional testing will be done at the time of collection to ensure there are adequate antibodies against the COVID-19 virus in the donors plasma to be part of the trial.

Registered convalescent plasma donors who may be eligible are being contacted now and all convalescent plasma donation appointments are being booked as donors are qualified to participate by Canadian Blood Services Centre for Innovation which oversees research and development for the organization.

Canadian Blood Services is not accepting walk-in donors for any of its collection programs during the pandemic.

Media assets

As per current physical distancing measures, media are not permitted to visit Canadian Blood Services donor centres. To ensure media have access to assets necessary to provide coverage, raw footage and an uncut interview with Canadian Blood Services first convalescent plasma donor will be made available.

Web-based interviews with Mr. Glubisz and with convalescent plasma donors in other areas of Canada may also be arranged through Canadian Blood Services.

Please contact media@blood.ca for more information.

About Canadian Blood Services

Canadian Blood Services is a not-for-profit charitable organization. Regulated by Health Canada as a biologics manufacturer and primarily funded by the provincial and territorial ministries of health, Canadian Blood Services operates with a national scope, infrastructure and governance that make it unique within Canadian healthcare. In the domain of blood, plasma and stem cells, we provide services for patients on behalf of all provincial and territorial governments except Quebec. The national transplant registry for interprovincial organ sharing and related programs reaches into all provinces and territories, as a biological lifeline for Canadians.

About Canadian Blood Services Research Activities

Canadian Blood Services, through its Centre for Innovation, conducts and supports research projects in key priority areas that span the translational continuum from bench to bed side. The focus is on transfusion science and medicine but also related fields such as cellular therapies (in particular hematopoietic stem cell transplantations) and organ and tissue transplantation. Our research findings are published in peer-reviewed journals or directly shared with stakeholders.

Instrumental to our research efforts are discovery and applied research laboratories led by university-affiliated Canadian Blood Services staff scientists, as well as our medical experts and adjunct scientists. Complementing these core research teams, the Centre for Innovation facilitates a national and international research network of blood system experts through competitive research funding opportunities, collaborations and contract research.

/CanadasLifeline@CanadasLifeline1 888 2DONATE

FOR MORE INFORMATIONTEL. 1-877-709-7773EMAILmedia@blood.ca

Read the original post:
First COVID-19 Convalescent Plasma DonorCanadian Blood Services begins collecting plasma donations from people who have recovered from COVID-19 as...

Remestemcel-L Looks Promising for COVID-19 With Moderate to Severe ARDS – Pulmonology Advisor

Home Topics Lung Infection

Mesoblast announced data from a phase 2/3 trial evaluating remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS).

Remestemcel-L consists of culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is believed to work by down-regulating the production of proinflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

The randomized, placebo-controlled trial is being conducted at Mount Sinai hospital in New York City. Patients were treated with a variety of experimental agents prior to receiving remestemcel-L. Findings from the study showed 83% survival in ventilator-dependent COVID-19 patients with moderate/severe ARDS (n=10/12) following 2 intravenous infusions of remestemcel-L within the first 5 days; 75% of patients (n=9/12) were able to successfully come off ventilator support at a median of 10 days. There have been 7 patients discharged from the hospital as of now.

Mesoblast Chief Executive Dr. Silviu Itescu stated: The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS. We intend to rapidly complete the randomized, placebo-controlled phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients.

Additionally, the Food and Drug Administration recently accepted for Priority Review the Biologics License Application of remestemcel-L for the treatment of steroid-refractory acute graft vs host disease. The Company expects to launch remestemcel-L in 2020 if approved.

For more information mesoblast.com.

This article originally appeared on MPR

Please login or register first to view this content.

LoginRegister

Next post in Lung InfectionClose

Read more here:
Remestemcel-L Looks Promising for COVID-19 With Moderate to Severe ARDS - Pulmonology Advisor

Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 – Latest Herald

Stem Cell Therapy market describes in-depth assessments and professional studies of the current and future status of the market worldwide, including valuable facts and figures. Stem Cell Therapy markets enhance this growth trend by providing information on new opportunities and market drivers, trends and future technologies. This report defines scope, coverage, production and CAGR (%) according to type, share, revenue status and outlook, capacity, consumption, market drivers, production status and outlook and opportunities, exports, imports, emerging market / national growth rates. This report provides a 360-degree overview of the industrys competitive environment. The Stem Cell Therapy market report evaluates key regions (countries) with a large market share during the forecast period.

Get sample copy of Stem Cell Therapy Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/691

The research in its endeavor to present an unbiased presentation of the Stem Cell Therapy market, complete with multi-faceted documentation of various market forces that collectively lend enormous growth impetus to the Stem Cell Therapy market. This report further reinforces vital statistical data on technological marvels that under prevailing circumstances direct growth in the Stem Cell Therapy market. A holistic understanding on PESTEL and SWOT analysis are also tagged in the report to unearth peculiarities of the Stem Cell Therapy market.

Full Browse the report description and TOC: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Furthermore, Report provides the deep analysis about the impact of domestic and global players on market, trade regulation, value chain optimization, and opportunities analysis for new present as well as new players, recent developments, strategic market growth analysis, area marketplace expanding, product launches, technological innovations and many more. The study report of global Stem Cell Therapy market can be split on the basis of key segments such as product type, application, key companies and key regions. Also the growth of the global Stem Cell Therapy market can be projected on the basis of segments and calculation for sales by application and type of the product in terms of volume and value.

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

This market ready research offering on Stem Cell Therapy market is a go-to synopsis that highlights on all the core developments simultaneously dominant across all regional hubs in the Stem Cell Therapy market and their subsequent implications on holistic growth trajectory of Stem Cell Therapy market globally. The report is aimed at answering all the relevant queries pertaining to the target market based on which successful business decisions could be rapidly applied, favoring uncompromised growth in the Stem Cell Therapy market.

The report also lends light on competition spectrum, highlighting core market participants who are identified as frontline players in Stem Cell Therapy market as highlighted by this research. In its bid to equip players with real time understanding of the various operational factors dominant across regions, the research elaborating on Stem Cell Therapy market also houses crucial data on various geographical hubs identified in Stem Cell Therapys market as presented.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Go here to see the original:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Latest Herald

Cancer Stem Cell Therapies: Mapping the Future Growth Potential – Communal News

The objective of the ongoing R&D in this domain is to develop novel CSC directed treatments that can combat complications, such as off-target toxicities and disease relapse, associated with the current standard of care treatments.TheCancer Stem Cell Therapies Market, 2017-2030report examines the current landscape and the future outlook of the growing pipeline of products targeting CSCs.Some of the most interesting insights from our study are presented below.

CSCs have Garnered a Lot of Interest Across Different PlatformsIncreasing chatter on social media, and the fact that over 9,000 scientific articles have been published in the last few years, indicate the growing interest in this domain

A Robust Pipeline Offers Significant Future PotentialWith two commercialized drugs and close to 150 clinical/preclinical molecules, the field has evolved significantly over time and has several promising candidate therapies

A Healthy Mix of Small Molecules and Biologics, The growing pipeline features both small molecule and biologic product candidates, which are being developed to target a number of cancer stem cell regulatory pathways

Being Designed for Novel Targets, Reinforces the Underlying PromiseSpecifically, over 70 clinical-stage molecules are being investigated to tap opportunities across different types of cancer

The US and the EU are Key Innovation HubsBoth big and small pharma players are actively involved; the US and EU are currently leading the research efforts

The Market is Expected to Witness Rapid Growth in the Mid-Long TermAfter the approval and launch of multiple late-phase product candidates, the market is expected to grow at a rapid pace

The Opportunity is Likely to be Well Distributed Across Indications and TargetsThe emergence of effective therapeutic strategies will result in better opportunities in the long term as more drugs get approved for a diverse range of indications

To know more please clickhere For any queries/suggestions or if youd like to get access to the full research results, please do not hesitate to contact us atsales@rootsanalysis.com

Continue reading here:
Cancer Stem Cell Therapies: Mapping the Future Growth Potential - Communal News

Macomb County doctor charged health care fraud over COVID-19 treatments – Detroit Free Press

The founder of Allure Medical Spa, the Shelby Township business raided by federal officials last week, is accused of health care fraud that includes using the COVID-19 pandemic "as an opportunity to bill insurers for Vitamin-C infusions fraudulently represented as COVID-19 treatments and preventative measures."

Dr. Charles Mok is the only defendant listed in the 47-page complaint unsealed Tuesday in U.S. District Court in Detroit. The 56-year-old Washington Township man is charged with health care fraud and conspiracy to commit health care fraud in the complaint dated Friday.

His attorney, Mark Kriger, had no comment Tuesday morning.Mok is scheduled for an initial appearance in court at 1 p.m. Tuesday.

The complaint discusses multiple millions of dollars in billings to Medicare from Jan. 1, 2018 to April 7 of this year.

It alleges that Mok engaged in a scheme to defraud prior to and during the coronavirus pandemic through the submission of false and fraudulent claims to Medicare for payment related to the treatment of varicose veins.

The complaint also states he failed to observe appropriate protocols at the clinic to minimize the spread of the virus.

A cooperating witness, who is an employee, was aware of five employees who tested positive for the virus but continued to work and treat patients at Allure, according to the complaint.

Federal Bureau of Investigations evidence response team members head into the building where Allure Medical's office is in Shelby Township, Michigan on Thursday, April 23, 2020.The Federal Bureau of Investigations raided Allure Medical for an alleged "federal violation."(Photo: Eric Seals, Detroit Free Press)

FBI investigators raided the location near 26 Mile and Van Dyke last Thursday. TheU.S. Department of Health and Human Services was part of the task force.

More: FBI raids Allure Medical Spa in Shelby Township for alleged fraudulent COVID-19 treatments

A woman who answered the phone at the Allure Medical location the day of the raid she did not have anyone available to talk with a Free Press reporter. Messages left at the location and via email that day were not returned.

Allure Medical has eight locations in Michigan, as well as offices in Florida, Kentucky, North Carolina and South Carolina, according to its website.

It statedthe Shelby Township location offers varicose vein treatment, hormone replacement therapy, dermatology, stem cell therapy, cosmetics and weight loss services.

The building where Allure Medical's office is in Shelby Township, Michigan on Thursday, April 23, 2020.The Federal Bureau of Investigations raided Allure Medical for an alleged "federal violation."(Photo: Eric Seals, Detroit Free Press)

According to SRQ Magazine, Allure Medical was offering high-dose intravenous vitamin C therapy to front-line employees who are at risk of contracting the virus and to existing COVID-19 patients. Front-line workers are identified as those who include hospital staff, police and first responders, and grocery store employees.

The magazine quoted Mok as saying We are using high-dose IV vitamin C to help support people's immune systems and to help those with the virus recover quicker. We want to provide this treatment to those who need it, regardless of their ability to pay."

The magazine statedthat Allure Medical won't treat sick people at the same time as those who are healthy.

Contact Christina Hall: chall@freepress.com. Follow her on Twitter: @challreporter.

Read or Share this story: https://www.freep.com/story/news/local/michigan/macomb/2020/04/28/allure-medical-spa-shelby-covid-vitamin-c/3038801001/

Read more:
Macomb County doctor charged health care fraud over COVID-19 treatments - Detroit Free Press

The impact of the coronavirus on the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Volume Analysis, size, share and Key Trends…

Analysis of the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The recent market study suggests that the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is expected to grow at a CAGR of ~XX% between 2019 and 2029 and reach a value of ~US$XX by the end of 2029.

The study offers a microscopic view of the various segments and sub-segments of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market and accurately represents the data using informative tables, graphs, and figures. The objective of the report is to assist readers to make informed business decisions and improve their position in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market landscape post the COVID-19 pandemic.

Request Sample Report @https://www.mrrse.com/sample/18928?source=atm

Vital data enclosed in the report:

Segmentation Analysis of the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market study offers a detailed understanding of the consumption, demand, and pricing structure of each product.

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market report evaluates how the Platelet Rich Plasma and Stem Cell Alopecia Treatment is being utilized by various end-users.

By Region

The report offers valuable insights related to the growth prospects of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in different regions including:

Companies Mentioned in the Report

The report also profiles major players operating in the global platelet rich plasma & stem cell alopecia treatment market based on various attributes, such as company overview, financial overview, pipeline portfolio, product portfolio, business strategies, and recent developments. The players covered in the report include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy.

The global platelet rich plasma & stem cell alopecia treatment market has been segmented as below:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/18928?source=atm

Questions Related to the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Catered to in the Report:

Buy This Report @ https://www.mrrse.com/checkout/18928?source=atm

Read the original post:
The impact of the coronavirus on the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Volume Analysis, size, share and Key Trends...

Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) – Jewish Life News

GlobalStem Cell Therapy Market, delivering a must-read report for industry stakeholders wanting to understand the strategic landscape of this burgeoning sector. Readers will find an in-depth analysis of the market and how it will impact existing traditional markets, as well as insights into future development and opportunities across the globe.

MarketInsightsReports has announced the addition of the Global Stem Cell Therapy Market Research Report 2020 The report focuses on global major leading players with information such as company profiles, product picture and specification.

Get Sample Copy of Stem Cell Therapy Market Report

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/inquiry?Mode=10

Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix), request free sample for complete list of companies.

The leading players of industry, their market share, product portfolio, company profiles are covered in this report. The competitive market scenario among players will help the industry aspirants in planning their strategies.

Summary

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell Therapy market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell Therapy industry.

Stem Cell Therapy Market Segmentation by types, Applications and regions:

Market Segment by Type covers:

Autologous

Allogeneic

Market Segmented by Applications:

Musculoskeletal Disorder

Wounds & Injuries

Cornea

Cardiovascular Diseases

Others

Market Segment by Regions:

North America (the United States, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.)

Available [emailprotected] (Exclusive new year offer Flat 20%- Use code MIR 20):

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/discount?Mode=10

These segments are thoroughly evaluated on an individual basis and a team of analysts has ensured to give a crystal clear idea about various lucrative segments of the industry. This detailed analysis using segmentation by providing precise results on industry-related markets.

The report also analyzed the evolution of industry trends. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the industry.

Frequently Asked Questions about global market:

Customization of the Report:This report can be customized as per your needs for additional data up to 3 companies or 3 countries or nearly 40 analyst hours.

Note:

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Visit complete report@

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026?Mode=10

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and Chinese and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Sales)

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

More:
Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) - Jewish Life News

Somatic Driver Mutations Leading to Endometrial Cancer Occur Early in Life – Cancer Therapy Advisor

Home Cancer Topics Gynecologic Cancer

Whole-genome DNA sequencing studies of normal endometrial glandulartissue have revealed the frequent presence of somatic driver mutations in cancer-relatedgenes. These findings were published in Nature.

While the acquisition of mutations overtime is believed to be a characteristic of all somatic cells, data are limitedon how it occurs in normal tissues.Nevertheless, the study authors noted that [t]he characterizationof the mutational landscapes of normal tissues isadvancing our understanding of the succession of intermediate neoplastic stages between normalcells and the cancers that originate fromthem.

One of the rationales for focusing on theendometrium of the uterus was related to its highly dynamic physiology duringthe reproductive years in response to fluctuating hormone levels, as well asits composition of stromal cells covered by a surface epithelium that iscontiguous with embedded glandular epithelium. Although the contiguity of thesurface epithelial sheet and the glandular tissue is disrupted duringmenstruation, it is subsequently restored by stem cells within retained embeddedglands.

In this study, 292 normal endometrialglands were isolated using laser-capture microdissection from 28 women between theages of 19 and 81 years. Comparisons of whole-exome DNA sequencing results forthese tissues with matched specimens of other types of normal tissue from thesame individual were used to identify somatic mutations in the endometrialglandular tissue. Corresponding data on patient age and parity allowed for theexploration of these factors on the rate and timing of somatic driver mutationsin normal glandular tissue of the endometrium.

Some of the keyfindings of this study included the following:

In their concluding remarks, the study authors noted that their results show that mutational landscapes differ markedly between normal tissues perhaps shaped by differences in their structure and physiology and indicate that the procession of neoplastic change that leads to endometrial cancer is initiated early in life.

Reference

Moore L, Leongamornlert D, Coorens THH, et al. The mutational landscape of normal human endometrial epithelium [published online April 22, 2020]. Nature. doi: 10.1038/s41586-020-2214-z

Please login or register first to view this content.

LoginRegister

Next post in Gynecologic CancerClose

Continue reading here:
Somatic Driver Mutations Leading to Endometrial Cancer Occur Early in Life - Cancer Therapy Advisor

Stem Cell Therapy Shows 83% Survival in COVID-19 Patients Dependent on Ventilator – HospiMedica

Ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) who were treated with intravenous infusions of an allogeneic mesenchymal stem cell product candidate had a survival rate of 83%.

The allogeneic mesenchymal stem cell product candidate remestemcel-L from Mesoblast Limited (Melbourne, Australia) was administered within the first five days under emergency compassionate use at New York Citys Mt Sinai hospital during the period March-April 2020. Patients received a variety of experimental agents prior to remestemcel-L. All patients were treated under an emergency Investigational New Drug (IND) application or expanded access protocol at Mt Sinai hospital. 75% of the patents successfully came off ventilator support within a median of 10 days, in contrast to only 9% of ventilator-dependent COVID-19 patients being able to come off ventilators with standard of care treatment and only 12% survival in ventilator-dependent COVID-19 patients at two major referral hospital networks in New York during the same time period. These poor outcomes are consistent with earlier published data from China where mortality rates of over 80% were reported in patients with COVID-19 and moderate/severe ARDS.

The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS, said Mesoblast Chief Executive Dr. Silviu Itescu. We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients.

There is a significant need to improve the dismal survival outcomes in COVID-19 patients who progress to ARDS and require ventilators, said Mesoblast Chief Medical Officer Dr Fred Grossman. We have implemented robust statistical analyses in our Phase 2/3 trial as recommended by the US Food and Drug Administration (FDA) in order to maximize our ability to evaluate whether remestemcel-L provides a survival benefit in moderate/severe COVID-19 ARDS.

Related Links:Mesoblast Limited

Excerpt from:
Stem Cell Therapy Shows 83% Survival in COVID-19 Patients Dependent on Ventilator - HospiMedica